Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers
Authors:
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 268, 120528
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health
This publication has 64 references indexed in Scilit:
- Nanoparticle clearance is governed by Th1/Th2 immunity and strain backgroundJournal of Clinical Investigation, 2013
- The Role of Endosomal Escape and Mitogen-Activated Protein Kinases in Adenoviral Activation of the Innate Immune ResponsePLOS ONE, 2011
- Induction of Shock After Intravenous Injection of Adenovirus Vectors: A Critical Role for Platelet-activating FactorMolecular Therapy, 2010
- Cancer-induced Expansion and Activation of CD11b+Gr-1+ Cells Predispose Mice to Adenoviral-triggered Anaphylactoid-type ReactionsMolecular Therapy, 2009
- Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated ratsJournal of Hepatology, 2005
- The Signaling Pathways Induced by Neutrophil-Endothelial Cell AdhesionAntioxidants & Redox Signaling, 2002
- Side‐effects of a systemic injection of linear polyethylenimine–DNA complexesThe Journal of Gene Medicine, 2001
- Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsisCritical Care Medicine, 1994
- In vivo responses of mouse blood cells to platelet-activating factor (PAF): Role of the mediators of anaphylaxisInflammation Research, 1993
- Biologically active products of stimulated liver macrophages (Kupffer cells)European Journal of Biochemistry, 1990